Current status and future prospects of array-based comparative genomic hybridisation.
The majority of human cancers as well as many developmental abnormalities harbour chromosomal imbalances, many of which result in the gain and/or loss of genomic material. Conventional comparative genomic hybridisation (CGH) has been used extensively to map DNA copy number changes to chromosomal positions. The introduction of microarray CGH provided a powerful tool to precisely detect and quantify genomic aberrations and map these directly onto the sequence of the human genome. In the past several years, a number of different approaches towards array-based CGH have been undertaken. This paper reviews these approaches and presents some of the recently-developed applications of this new technology in both research and clinical settings.
Snijders
Antoine M
AM
University of California Comprehensive Cancer Center, USA.
Pinkel
Daniel
D
Albertson
Donna G
DG
D002869:Chromosome Aberrations; D004273:DNA, Neoplasm / Q000032:analysis; D018628:Gene Dosage; D005819:Genetic Markers; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D009369:Neoplasms / Q000235:genetics / Q000473:pathology; D009693:Nucleic Acid Hybridization / Q000379:methods*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*
D004273:DNA, Neoplasm; D005819:Genetic Markers